Key clinical point: Chimeric antigen receptor natural killer cells may be an effective off-the-shelf therapy for advanced lymphoid cancers.
Major finding: Seven of 11 patients had complete remissions after a single infusion of CAR-NK cells.
Study details: Phase 1/2 trial of CAR-NK cell therapy in 11 patients with heavily pretreated lymphoid malignancies.
Disclosures: The National Institutes of Health supported the study. Dr. Liu disclosed a pending patent for methods of production of CAR-NK cells, and a patent held by MD Anderson for methods of treatment with NK cells. Dr. Hill is a member of the Hematology News editorial advisory board.
Liu E et al. N Engl J Med. 2020 Feb 6;382:545-53.